# China Pharma Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2017

- Company: [China Pharma Holdings, Inc.](/companies/cphi.md) (CIK 1106644)
- Form: 10-Q
- Filed: 2017-05-11
- Accepted by EDGAR: May 11, 2017, 17:02 ET
- Period: 2017-03-31
- Accession: 0001010549-17-000167
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1106644/000101054917000167/cphi10q033117.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1106644/000101054917000167/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-01-01 to 2017-03-31 | $3.3m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2017-01-01 to 2017-03-31 | $2.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2017-01-01 to 2017-03-31 | $717.9k | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-01-01 to 2017-03-31 | $26.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-01-01 to 2017-03-31 | −$802.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-01-01 to 2017-03-31 | −$139.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2017-01-01 to 2017-03-31 | −$966.9k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-01-01 to 2017-03-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2017-01-01 to 2017-03-31 | $9.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2017-01-01 to 2017-03-31 | −$26.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | at 2017-03-31 | $17.5m | us-gaap:AssetsCurrent |
| Total assets | at 2017-03-31 | $78.1m | us-gaap:Assets |
| Current liabilities | at 2017-03-31 | $10.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-03-31 | $19.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2017-03-31 | $58.4m | us-gaap:StockholdersEquity |

## Market risk

As filed, 139 characters.

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.

## Controls and procedures

As filed, 1,645 characters.

### Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our "disclosure controls and procedures" (as defined in the Securities Exchange Act of 1934 (the "Exchange Act") Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2017, due to ineffective internal controls over financial reporting that stemmed our lack of accounting financial reporting personnel knowledgeable in US GAAP.

### Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed May 11, 2017.
Source: SEC EDGAR, the filing index for accession 0001010549-17-000167. Last ingested by Listed: Oct 30, 2026, 16:51 ET. No prices; not investment advice.